Skip to content

Study · Non-randomized trial · 1990

5 results

Vasoactive intestinal polypeptide and human vaginal blood flow: comparison between transvaginal and intravenous administration.

Palle C, Bredkjaer HE, Ottesen B, Fahrenkrug J

Clinical and experimental pharmacology & physiology1 Jan 1990Cited by 19 (Europe PMC)

PMID2350902 (opens in a new tab)DOI10.1111/j.1440-1681.1990.tb01265.x (opens in a new tab)PepBankPUB-02350902
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal women, subepithelial and intravenous VIP each caused a significant dose-dependent increase in vaginal blood flow, with the same efficacy, potency and sensitivity.

    In plain wordsIn healthy women, VIP given under the vaginal lining or into a vein raised vaginal blood flow, with similar effect by both routes.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVaginal blood flow
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    increasing doses · vaginal subepithelial and intravenous injectionAs given in this study (human).

    Source sentences

    Summary
    Both subepithelial and intravenous injections induced a significant and dose-dependent increase in vaginal blood flow (P less than 0.05), displaying the same efficacy, potency and sensitivity.
    1 context sentence
    Summary · context
    The present study was performed to examine and compare the effect of increasing doses of vasoactive intestinal polypeptide (VIP) on vaginal blood flow following vaginal subepithelial and intravenous injection in normal women.
  2. 02HumanNon-randomized trialPharmacokinetics

    In normal women, vaginal blood flow values correlated with plasma VIP concentrations after both routes of administration.

    In plain wordsIn healthy women, vaginal blood flow was linked to the VIP level in blood after both routes.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableCorrelation of vaginal flow with plasma VIP
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Reproductive and sexual health
    Studied dose
    increasing doses · vaginal subepithelial and intravenous injectionAs given in this study (human).

    Source sentences

    Summary
    The vaginal flow values correlated with the corresponding plasma VIP concentrations after both routes of administration.
    1 context sentence
    Summary · context
    The present study was performed to examine and compare the effect of increasing doses of vasoactive intestinal polypeptide (VIP) on vaginal blood flow following vaginal subepithelial and intravenous injection in normal women.
  3. 03HumanNon-randomized trialSafety outcome

    In normal women, flushing occurred after both subepithelial and intravenous VIP.

    In plain wordsIn healthy women, flushing occurred after VIP by both routes.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseFlushing
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    increasing doses · vaginal subepithelial and intravenous injectionAs given in this study (human).

    Source sentences

    Summary
    The systemic vascular side effects; that is, flushing, hypotension and tachycardia, were observed following both subepithelial and intravenous injection.
    1 context sentence
    Summary · context
    The present study was performed to examine and compare the effect of increasing doses of vasoactive intestinal polypeptide (VIP) on vaginal blood flow following vaginal subepithelial and intravenous injection in normal women.
  4. 04HumanNon-randomized trialSafety outcome

    In normal women, hypotension occurred after both subepithelial and intravenous VIP.

    In plain wordsIn healthy women, low blood pressure occurred after VIP by both routes.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseHypotension
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    increasing doses · vaginal subepithelial and intravenous injectionAs given in this study (human).

    Source sentences

    Summary
    The systemic vascular side effects; that is, flushing, hypotension and tachycardia, were observed following both subepithelial and intravenous injection.
    1 context sentence
    Summary · context
    The present study was performed to examine and compare the effect of increasing doses of vasoactive intestinal polypeptide (VIP) on vaginal blood flow following vaginal subepithelial and intravenous injection in normal women.
  5. 05HumanNon-randomized trialSafety outcome

    In normal women, tachycardia occurred after both subepithelial and intravenous VIP.

    In plain wordsIn healthy women, a fast heart rate occurred after VIP by both routes.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseTachycardia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    increasing doses · vaginal subepithelial and intravenous injectionAs given in this study (human).

    Source sentences

    Summary
    The systemic vascular side effects; that is, flushing, hypotension and tachycardia, were observed following both subepithelial and intravenous injection.
    1 context sentence
    Summary · context
    The present study was performed to examine and compare the effect of increasing doses of vasoactive intestinal polypeptide (VIP) on vaginal blood flow following vaginal subepithelial and intravenous injection in normal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.